KKR to Acquire Medicover’s India Hospital Operations in €1.2 Billion Deal

Date:

Share post:

Global investment firm KKR has signed definitive agreements to acquire 100% of Medicover India, the hospital operations of Stockholm-listed healthcare and diagnostic provider MedicoverAB, at an enterprise value of €1.2 billion (approximately $1.4 billion).

Under the terms of the agreement, KKR-managed funds will acquire both the 66.1% stake held by Medicover AB and the remaining 33.9% stake held by minority shareholders. The divestment will yield gross cash proceeds of approximately €740 million ($855 million) for Medicover AB, allowing the Swedish firm to focus strategically and operationally on its core European markets, including Poland, Germany, and Romania.

Established in 2017, Medicover India operates a multi-specialty hospital network of 24 hospitals with approximately 4,800 beds across southern and western India. Supported by more than 1,900 doctors spanning over 80 clinical specialties, the network serves millions of patients annually and generated €220.5 million in revenue over the 12 months ending June 30, 2026.

“This transaction represents an important milestone in supporting the long-term growth of India’s healthcare infrastructure,” said Akshay Tanna, Partner and Head of India Private Equity at KKR. KKR plans to support Medicover India’s clinicians and staff to expand patient access to high-quality care and advanced clinical solutions.

The transaction is subject to regulatory and merger-control approvals and is expected to close in the fourth quarter of 2026.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

ViiV Healthcare Advances HIV Care with Breakthrough Long-Acting Injectable Data at AIDS 2026

ViiV Healthcare, the global specialist HIV company majority-owned by GSK plc, announced landmark clinical, real-world, and pipeline data...

Wockhardt Launches “Wockhardt Antibiotic Academy” to Tackle Growing Threat of Multidrug Resistance in India

Wockhardt Limited announced the launch of the Wockhardt Antibiotic Academy, a national initiative dedicated to fostering patient-centric scientific dialogue...

Optimus Pharma Secures Regulatory Approval for Non-Steroidal Tapinarof Cream to Treat Plaque Psoriasis

Optimus Pharma, a leading Indian pharmaceutical manufacturer and subsidiary of Sekhmet Pharmaventures, announced that it has received regulatory...

Enhertu Shows Better Results Than Standard Treatment in Lung Cancer Trial

AstraZeneca and Daiichi Sankyo announced that their antibody-drug conjugate Enhertu (trastuzumabderuxtecan) has achieved a statistically significant and clinically meaningful improvement...